Obinutuzumab Plus Chemotherapy Compared with Rituximab Plus Chemotherapy in Previously Untreated Italian Patients with Advanced Follicular Lymphoma at Intermediate–High Risk: A Cost-Effectiveness Analysis

OBJECTIVE: To assess the cost-effectiveness of obinutuzumab (O-chemo) in comparison to rituximab (R-chemo) in patients with untreated advanced follicular lymphoma (FL) at intermediate or high risk from an Italian National Health Service (NHS) perspective. METHODS: A previously developed four-state M...

Descripción completa

Detalles Bibliográficos
Autores principales: Bellone, Marco, Pradelli, Lorenzo, Molica, Stefano, De Francesco, Adele Emanuela, Ghislieri, Daniela, Guardalben, Emanuele, Caputo, Antonietta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313400/
https://www.ncbi.nlm.nih.gov/pubmed/34321898
http://dx.doi.org/10.2147/CEOR.S317885

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313400/
https://www.ncbi.nlm.nih.gov/pubmed/34321898
http://dx.doi.org/10.2147/CEOR.S317885

Ejemplares similares